A case with catecholaminergic polymorphic ventricular tachycardia

Yıl 2011, Cilt: 2 Sayı: 2, 232 - 234, 01.06.2011

Hüseyin Uğur Yazıcı Kadir Uğur Mert Muharrem Nafisov Ahmet Ünalır Bülent Görenek

https://doi.org/10.5799/ahinjs.01.2011.02.0247

Öz

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare type of polymorphic ventricular tachycardias in individuals without structural cardiac abnormalities. It typically has been induced by exercise or emotional stres. It generally is seen in childhood and adolescent period but rarely is seen in elderly. It usually ends by spontaneus, but rarely cause hemodynamic collapse. In here, we present a case with CPVT of successful treatment with a beta blocker therapy.

Anahtar Kelimeler

Catecholaminergic, ventricular tachycardia

Katekolaminerjik polimorfik ventrikül taşikardili bir olgu

Öz

Katekolaminerjik polimorfik ventrikül taşikardisi yapısal kalp hastalığı yokluğunda görülen polimorfik ventrikül taşikardilerinin nadir bir çeşididir. Tipik olarak egzersiz ya da emosyonel stres tarafından indüklenir. Sıklıkla çocukluk ve adölesan dönemde görülmekle birlikte ilerleyen yaşlarda da açığa çıkabilir. Genellikle kendiliğinden sonlanır, fakat nadiren hemodinamik kollapsa neden olabilir. Burada katekolaminerjik ventrikül taşikardisi tanısı konulup beta bloker tedavi ile başarılı tedavisi yapılan bir olgu sunuldu.

Anahtar Kelimeler

Katekolaminerjik, ventrikül taşikardisi

Kaynakça

• 1. Wren C, Rowland E, Burn J, Campbell RW. Familial ventricular tachycardia: a report of four families. Br Heart J 1990; 63(5):169- 70.
• 2. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106(1):69-74.
• 3. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995; 91(10):1512-9.
• 4. Ylänen K, Poutanen T, Hiippala A, et al. Catecholaminergic polymorphic ventricular tachycardia. Eur J Pediatr 2010;169(4):535-42.
• 5. Swan H, Piippo K, Viitasalo M, et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol 1999; 34(12):2035-42.
• 6. Lahat H, Eldar M, Levy-Nissenbaum E, et al. Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation 2001; 103(11):2822-7.
• 7. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death-Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48(8):1064-9.
• 8. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.
• 9. Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 2009; 119:2426-34.
• 10. Wilde AA, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med; 2008:358(11):2024-9.